New York Regeneron Pharmaceuticals Inc shares -0.09% dropped 0.09% to $586.35 Friday. However, this proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX, +1.01% rising 1.01% to 4,411.79 and the Dow Jones Industrial Average DJIA, +0.68% rising 0.68% to 35,061.55.
Regeneron Pharmaceuticals Inc. closed $73.65 below its 52-week high ($660.00), which the company achieved on August 5th.The stock crashed when compared to some of its competitors Friday, as Johnson & Johnson JNJ, +1.06% rose 1.06% to $171.79, Novartis AG ADR NVS, +0.54% rose 0.54% to $91.57, and Amgen Inc. AMGN, +1.22% rose 1.22% to $247.72.
The volatility in the company’s stock is being driven by the developments for REGEN-COV, its Covid-19 antibody cocktail. However, over the past few months, we have maintained our view that REGN stock has more room for growth, given the long-term growth potential of some of its drugs, including Eylea and Dupixent. Eylea, an ophthalmology drug, is expected to continue to garner over $7 billion in annual sales for the next few years, while Dupixent, eczema and asthma drug is expected to garner over $12 billion in peak sales. After moving 0.9% or more over ten days, the stock rose in the next ten days on 51% of the occasions